Nov 21, 2019: Harpoon Therapeutics, Inc. a clinical-stage immunotherapy company developing a novel class of T cell engagers, and AbbVie Inc, a global biopharmaceutical company, announced an elite worldwide option and license transaction for HPN217, Harpoon’s B cell maturation antigen (BCMA)-targeting Tri-specific T cell Activating Construct (TriTAC®), and an expansion of their existing discovery collaboration for up to six additional targets established by the two companies in October 2017.
The TriTAC platform produces novel T cell engagers targeting both solid tumors and hematologic malignancie.“Harpoon has built a unique and unshared biologics platform that utilizes the patient’s own immune system to attack cancer. HPN217, targeting BCMA, is poised to proceed to clinical development for the treatment of multiple myeloma”,
Harpoon’s BCMA TriTAC combined with AbbVie’s development expertise, has the potential to generate innovative new medicines for patients with cancer. Under the terms of the license and option agreement, Harpoon granted to AbbVie an option to license worldwide exclusive rights to HPN217 through Phase 1/2 clinical trials. https://news.abbvie.com/news/press-releases/harpoon-therapeutics-and-abbvie-announce-licensing-and-option-collaboration-to-advance-hpn217-harpoons-bcma-targeting-tritac-and-expand-existing-discovery-collaboration.htm